Genprex, Inc.
NASDAQShort sellers have built one of the most extreme positions in the micro-cap biotech universe heading into GNPX's Q1 results today, and the borrow market confirms the pressure isn't easing. Short interest has more than doubled in a month — up 117% — to reach 73.8% of the free float, an extraordinary level for any stock at any size. The lending market underscores how aggressive this…
GNPX short interest plunges 22.8% in one week to 59.4% of float; cost to borrow eases to 17.4%.
Snapshot as of 23 Jun 2026
Short sellers have built one of the most extreme positions in the micro-cap biotech universe heading into GNPX's Q1 results today, and the borrow market confirms the pressure isn't easing. Short interest has more than…
Genprex, Inc. enters its Q1 2026 earnings print — released today after market — with short sellers having aggressively rebuilt positions over the past month, the stock already 28% lower, and a deeply oversold tape that…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GNPX — free to start on ORTEX.
Sign up for free →Open GNPX on ORTEX